Drugs / FLT201
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT05324943 | Apr 2022 → Dec 2024 | Gaucher disease type I | Spur Therapeutics | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT06545136 | May 2024 → May 2029 expected | Gaucher disease type I | Spur Therapeutics | Active not recruiting | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT07223944 | Apr 2026 → Jul 2028 expected | Gaucher disease type I | Spur Therapeutics | Recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | FLT201 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05324943 ↗ |
| Action | Restore | “augmentation of residual glucocerebrosidase (GCase) expression” NCT05324943 ↗ |
| Modality | Gene therapy (AAV / viral vector) | “FLT201 is a replication-incompetent single-stranded (ss) recombinant adeno-associated virus (AAV) vector.” NCT05324943 ↗ |
| Route | Intravenous | “administered as a single intravenous infusion” NCT05324943 ↗ |